1.Second metabolites comparative analysis of Codonopsis pilosula  (Franch.) Nannf. from different origins based on extensively targeted metabolomics
		                			
		                			Ling-yu LI ; De-fu WANG ; Zhen-fang LI ; Shao-fei SHEN ; Hong-ling TIAN ; Yan-bing NIU
Acta Pharmaceutica Sinica 2023;58(11):3421-3427
		                        		
		                        			
		                        			 We performed an extensively targeting metabolomic detecting using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS/MS) to compare the secondary metabolites in Dang shen [
		                        		
		                        	
2.Knowledge and Use of Personal Protective Measures for Mitigating Acute Respiratory Infections in Children 6-16 Years of Age in Rural Communities of Macheng City, Hubei, China.
Yue CHEN ; Jian Bo ZHAN ; Shao Bo DONG ; Jian LU ; Jun Feng GUO ; Jin Song FAN ; Jing GE ; Xiao Jing LIN ; Yu LAN ; Kun QIN ; Bing HU ; Jian Fang ZHOU ; Cui Ling XU
Biomedical and Environmental Sciences 2022;35(10):968-975
3.The antitussive and expectorant mechanisms of deapio-platycodin D as determined by metabolomics
Yuan-han ZHONG ; Ling-long WANG ; Zi-chao QIU ; Shao-hui ZHONG ; Xin-hong WANG ; Jin-xiang ZENG ; Xin-yu ZHANG ; Fang-yuan LIU ; Yu-jie WANG ; Gen-lin SUN ; Li-fen ZHOU ; Guo-bing WEI ; Guo-yue ZHONG
Acta Pharmaceutica Sinica 2022;57(10):3186-3194
		                        		
		                        			
		                        			 The UHPLC-LTQ-orbitrap-MS metabolomics technique was used to determine the effect of deapio-platycodin D (DPD) on endogenous metabolites in lung tissues of mice with ammonia-induced cough, and to identify the metabolic regulatory pathways of DPD in its antitussive and expectorant activities. This work was approved by the Animal Ethics Committee of Jiangxi University of Chinese Medicine (Approval No. JZLLSC-20190235). Metabolites were identified by UHPLC-LTQ-orbitrap-MS method and the metabolic pathways related to differentially-expressed metabolites were analyzed by the MetaboAnalyst platform. DPD significantly prolonged (
		                        		
		                        	
4.Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study.
Cong Xiao ZHANG ; Shao Wei QIU ; Ben Fa GONG ; Xiao Yuan GONG ; Yan LI ; Yun Tao LIU ; Qiu Yun FANG ; Guang Ji ZHANG ; Kai Qi LIU ; Chun Lin ZHOU ; Shu Ning WEI ; Dong LIN ; Bing Cheng LIU ; Ying WANG ; Ying Chang MI ; Hui WEI ; Jian Xiang WANG
Chinese Journal of Hematology 2022;43(5):383-387
		                        		
		                        			
		                        			Objective: To compare the efficacy of two induction regimens, namely, idarubicin combined with cytarabine (IA) versus the combination of homoharringtonine, daunorubicin, and cytarabine (HAD) , in adult patients with newly diagnosed de novo acute myeloid leukemia (AML) . Methods: From May 2014 to November 2019, 199 patients diagnosed with AML receiving either the IA or HAD regimens were assessed for overall survival (OS) , relapse-free survival (RFS) , as well as the CR rate and the MRD negative rate after induction therapy. The differences in prognosis between the two induction therapy groups was assessed according to factors, including age, white blood cell (WBC) count, NPM1 mutation, FLT3-ITD mutation, 2017 ELN risk stratification, CR(1) transplantation, and the use of high-dose cytarabine during consolidation therapy, etc. Results: Among the 199 patients, there were 104 males and 95 females, with a median age of 37 (15-61) years. Ninety patients received the IA regimen, and 109 received the HAD regimen. Comparing the efficacy of the IA and HAD regimens, the CR rates after the first induction therapy were 71.1% and 63.3%, respectively (P=0.245) , and the MRD negative rates after the first induction therapy were 53.3% and 48.6%, respectively (P=0.509) . One patient in the IA group and two in the HAD group died within 60 days after induction. The two-year OS was 61.5% and 70.6%, respectively (P=0.835) , and the two-year RFS was 51.6% and 57.8%, respectively (P=0.291) . There were no statistically significant differences between the two groups. Multivariate analysis showed that the ELN risk stratification was an independent risk factor in both induction groups; CR(1) HSCT was an independent prognostic factor for OS and RFS in the IA patients and for RFS in the HAD patients but not for OS in the HAD patients. Age, WBC level, NPM1 mutation, and FLT3-ITD mutation had no independent prognostic significance. Conclusion: The IA and HAD regimens were both effective induction regimens for AML patients.
		                        		
		                        		
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
		                        			;
		                        		
		                        			Cytarabine/therapeutic use*
		                        			;
		                        		
		                        			Daunorubicin/therapeutic use*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Homoharringtonine/therapeutic use*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Induction Chemotherapy
		                        			;
		                        		
		                        			Leukemia, Myeloid, Acute/genetics*
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Nuclear Proteins
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Remission Induction
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Young Adult
		                        			
		                        		
		                        	
5.Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study.
Chun Hong LI ; Shu Ning WEI ; Shao Wei QIU ; Ben Fa GONG ; Xiao Yuan GONG ; Yan LI ; Yun Tao LIU ; Qiu Yun FANG ; Guang Ji ZHANG ; Kai Qi LIU ; Chun Lin ZHOU ; Dong LIN ; Bing Cheng LIU ; Ying WANG ; Ying Chang MI ; Hui WEI ; Jian Xiang WANG
Chinese Journal of Hematology 2022;43(4):287-292
		                        		
		                        			
		                        			Objective: To evaluate the efficacy and toxicity profiles of idarubicin, cytarabine, and cyclophosphamide (IAC) in relapse/refractory acute myeloid leukemia (AML) . Methods: This study was a prospective, randomized controlled clinical trial with the registration number NCT02937662. The patients were randomly divided into two groups. The experimental group was treated with an IAC regimen, and the regimen of the control group was selected by doctors according to medication experience. After salvage chemotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was conducted as far as possible according to the situation of the patients. We aimed to observe the efficacy, safety, and toxicity of the IAC regimen in relapse/refractory AML and to explore which is the better regimen. Results: Forty-two patients were enrolled in the clinical trial, with a median age of 36 years (IAC group, 22 cases and control groups, 20 cases) . ①The objective response rate was 71.4% in the IAC group and 40.0% in the control group (P=0.062) ; the complete remission (CR) rate was 66.7% in the IAC group and 40.0% in the control group (P=0.121) . The median follow-up time of surviving patients was 10.5 (range:1.7-32.8) months; the median overall survival (OS) was 14.1 (range: 0.6-49.1) months in the IAC group and 9.9 (range: 2.0-53.8) months in the control group (P=0.305) . The 1-year OS was 54.5% (95%CI 33.7%-75.3%) in the IAC group and 48.2% (95%CI 25.9%-70.5%) in the control group (P=0.305) , with no significant difference between these two regimens. ②The main hematologic adverse events (AEs) were anemia, thrombocytopenia, and neutropenia. The incidence of grade 3-4 hematologic AEs in the two groups was 100% (22/22) in the IAC group and 95% (19/20) in the control group. The median time of neutropenia after chemotherapy in the IAC group and control group was 20 (IQR: 8-30) and 14 (IQR: 5-50) days, respectively (P=0.023) . ③The CR rate of the early relapse (relapse within 12 months) group was 46.7% and that of the late relapse (relapse after 12 months) group was 72.7% (P=0.17) . The median OS time of early recurrence was 9.9 (range:1.7-53.8) months, and that of late recurrence patients was 19.3 (range: 0.6-40.8) months (P=0.420) , with no significant differences between the two groups. The 1-year OS rates were 45.3% (95%CI 27.2%-63.3%) and 66.7% (95%CI 40.0%-93.4%) , respectively (P=0.420) . Survival analysis showed that the 1-year OS rates of the hematopoietic stem cell transplantation group and non-hematopoietic stem cell transplantation group were 87.5% (95%CI 71.2%-100%) and 6.3% (95%CI 5.7%-18.3%) , respectively. The OS rate of the hematopoietic stem cell transplantation group was significantly higher than that of the non-hematopoietic stem cell transplantation group (P<0.001) . Conclusion: The IAC regimen is a well-tolerated and effective regimen in relapsed/refractory AML; this regimen had similar efficacy and safety with the regimen selected according to the doctor's experience for treating relapsed/refractory AML. For relapsed/refractory patients with AML, allogeneic hematopoietic stem cell transplantation should be attempted as soon as possible to achieve long-term survival.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
		                        			;
		                        		
		                        			Cyclophosphamide/therapeutic use*
		                        			;
		                        		
		                        			Cytarabine/therapeutic use*
		                        			;
		                        		
		                        			Hematopoietic Stem Cell Transplantation
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Idarubicin/therapeutic use*
		                        			;
		                        		
		                        			Leukemia, Myeloid, Acute/drug therapy*
		                        			;
		                        		
		                        			Neutropenia
		                        			;
		                        		
		                        			Prospective Studies
		                        			;
		                        		
		                        			Recurrence
		                        			;
		                        		
		                        			Retrospective Studies
		                        			
		                        		
		                        	
6.Inhibition of Ciliogenesis Enhances the Cellular Sensitivity to Temozolomide and Ionizing Radiation in Human Glioblastoma Cells.
Li WEI ; Wei MA ; Hui CAI ; Shao Peng PENG ; Huan Bing TIAN ; Ju Fang WANG ; Lan GAO ; Jin Peng HE
Biomedical and Environmental Sciences 2022;35(5):419-436
		                        		
		                        			Objective:
		                        			To investigate the function of primary cilia in regulating the cellular response to temozolomide (TMZ) and ionizing radiation (IR) in glioblastoma (GBM).
		                        		
		                        			Methods:
		                        			GBM cells were treated with TMZ or X-ray/carbon ion. The primary cilia were examined by immunostaining with Arl13b and γ-tubulin, and the cellular resistance ability was measured by cell viability assay or survival fraction assay. Combining with cilia ablation by IFT88 depletion or chloral hydrate and induction by lithium chloride, the autophagy was measured by acridine orange staining assay. The DNA damage repair ability was estimated by the kinetic curve of γH2AX foci, and the DNA-dependent protein kinase (DNA-PK) activation was detected by immunostaining assay.
		                        		
		                        			Results:
		                        			Primary cilia were frequently preserved in GBM, and the induction of ciliogenesis decreased cell proliferation. TMZ and IR promoted ciliogenesis in dose- and time-dependent manners, and the suppression of ciliogenesis significantly enhanced the cellular sensitivity to TMZ and IR. The inhibition of ciliogenesis elevated the lethal effects of TMZ and IR via the impairment of autophagy and DNA damage repair. The interference of ciliogenesis reduced DNA-PK activation, and the knockdown of DNA-PK led to cilium formation and elongation.
		                        		
		                        			Conclusion
		                        			Primary cilia play a vital role in regulating the cellular sensitivity to TMZ and IR in GBM cells through mediating autophagy and DNA damage repair.
		                        		
		                        		
		                        		
		                        			Antineoplastic Agents, Alkylating/therapeutic use*
		                        			;
		                        		
		                        			Brain Neoplasms/metabolism*
		                        			;
		                        		
		                        			Cell Line, Tumor
		                        			;
		                        		
		                        			DNA/therapeutic use*
		                        			;
		                        		
		                        			Glioblastoma/metabolism*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Radiation, Ionizing
		                        			;
		                        		
		                        			Temozolomide/therapeutic use*
		                        			
		                        		
		                        	
7.MiR-663a Inhibits Radiation-Induced Epithelium-to-Mesenchymal Transition by Targeting TGF-β1.
Pei QU ; Zhi Ang SHAO ; Bing WANG ; Jin Peng HE ; Ya Nan ZHANG ; Wen Jun WEI ; Jun Rui HUA ; Heng ZHOU ; Dong LU ; Nan DING ; Ju Fang WANG
Biomedical and Environmental Sciences 2022;35(5):437-447
		                        		
		                        			Objective:
		                        			miR-663a has been reported to be downregulated by X-ray irradiation and participates in radiation-induced bystander effect via TGF-β1. The goal of this study was to explore the role of miR-663a during radiation-induced Epithelium-to-mesenchymal transition (EMT).
		                        		
		                        			Methods:
		                        			TGF-β1 or IR was used to induce EMT. After miR-663a transfection, cell migration and cell morphological changes were detected and the expression levels of miR-663a, TGF-β1, and EMT-related factors were quantified.
		                        		
		                        			Results:
		                        			Enhancement of cell migration and promotion of mesenchymal changes induced by either TGF-β1 or radiation were suppressed by miR-663a. Furthermore, both X-ray and carbon ion irradiation resulted in the upregulation of TGF-β1 and downregulation of miR-663a, while the silencing of TGF-β1 by miR-663a reversed the EMT process after radiation.
		                        		
		                        			Conclusion
		                        			Our findings demonstrate an EMT-suppressing effect by miR-663a via TGF-β1 in radiation-induced EMT.
		                        		
		                        		
		                        		
		                        			Down-Regulation
		                        			;
		                        		
		                        			Epithelial-Mesenchymal Transition
		                        			;
		                        		
		                        			Epithelium/metabolism*
		                        			;
		                        		
		                        			MicroRNAs/metabolism*
		                        			;
		                        		
		                        			Transforming Growth Factor beta1/pharmacology*
		                        			
		                        		
		                        	
8. Exploration and Practice of the Mode of "3+X" in the Cultivation of Scientific Research and Innovation Ability of Medical Students
En-Min LI ; Hong SUN ; Hai-Ying ZOU ; Wang-Kai FANG ; Lin LONG ; Bing-Li WU ; Yin-Wei CHENG ; Wei-Jie XIE ; Li-Yan LI ; Shao-Yan ZHENH ; Li-Yan XU ; Miao YANG ; Guan-Hua FAN ; Mian-Hua YANG
Chinese Journal of Biochemistry and Molecular Biology 2022;38(3):381-392
		                        		
		                        			
		                        			 For a long time, the cultivation of medical students’ scientific research and innovation abilitymainly depends on scattered extracurricular scientific research activities. With limited students, unsystematic teaching and inadequate administrative guarantee, it often results in obvious weakness andinefficiency. Since 2002, the Biochemistry and Molecular Biology teaching team in Shantou UniversityMedical College has been working on a “3+X” model to nurture the scientific research and innovationability of medical students. Guided by the concepts of complementary development of science andeducation, student-centeredness, and Problem-based Learning, a model is established based on the‘HEART” professionalism courses and the academy culture specific to Shantou University. We also takefull advantage of the first-tier disciplines of biology, basic medicine and clinical medicine in ShantouUniversity and collaborate with other professional teaching teams. It is conceptualized in a framework thatembraces the comprehensive connotation of scientific research and innovation ability and adopts a corecurriculum system that runs through the 5-year medical undergraduate education. In this model, " 3" means " whole-person training", " whole-process training" and " omni-directional training" for medicalstudents; " X" refers to several confirmatory dimensions of the operational effectiveness of the " 3+X" model, including organizing medical students to participate in various forms of national college students’ innovative experimental research competitions, international college students’ academic seminars, writingand publishing academic papers by medical undergraduates as the first author, etc. The model proves tobe effective in cultivating the scientific research and innovation ability of medical students, hence settinga good example to solve the current problems in the cultivation of medical students’ scientific researchand innovation ability. 
		                        		
		                        		
		                        		
		                        	
9.Anatomical characteristics of patients with symptomatic severe aortic stenosis in China.
Tian-Yuan XIONG ; Yi-Ming LI ; Yi-Jun YAO ; Yu-Heng JIA ; Kai XU ; Zhen-Fei FANG ; Jun JIN ; Guo-Sheng FU ; Yi-Ning YANG ; Lei JIANG ; Wei-Dong LI ; Yan-Qing WU ; Yan-Song GUO ; Ran GUO ; Yun-Dai CHEN ; Yi LI ; Yi-Bing SHAO ; Yi ZHANG ; Bo-Sen YANG ; Yi-Ke ZHANG ; Jing-Jing HE ; Kai-Yu JIA ; Sheng-Hu HE ; Fa-Xin REN ; Jian-Cheng XIU ; Xing-Hua GU ; Liang-Long CHEN ; Ke HAN ; Yuan FENG ; Mao CHEN
Chinese Medical Journal 2021;134(22):2738-2740
10.China experts' consensus on preventive and interceptive orthodontic treatments of malocclusions of children.
Xiao-Bing LI ; Quan-Fu YE ; Hong HE ; Hai-Ping LU ; Min ZHU ; Ruo-Ping JIANG ; Shu-Juan ZOU ; Xiang-Long HAN ; Li ZHOU ; Ke CHEN ; Xiao YUAN ; Jun-Mei ZHANG ; Li-Jun TAN ; Chang YIN ; Zhou HE ; Ang LI ; Bin CHENG ; Wen-Hua RUAN ; Fang HUANG ; Juan LIU ; Lan MA ; Rui ZOU ; Fang YANG ; Wei-Bing ZHANG ; Yu-Lou TIAN ; Bei-Zhan JIANG ; Lin-Qin SHAO ; Yang HUANG ; Li-Qin TANG ; Li GAO ; Chen-Chen ZHOU
West China Journal of Stomatology 2021;39(4):369-376
		                        		
		                        			
		                        			Malocclusion is one of the three most common oral diseases reported by World Health Organization(WHO). In China, its incidence rate is rising. Malocclusion seriously affects the dental and maxillofacial function, facial appearance and growth development of nearly 260 million children in China, and what is more, it affects their physical and mental health development. Malocclusion occurrence is related to genetic and environmental factors. Early treatment of malocclusion can create a good dental and maxillofacial development environment, correct abnormal growth and control the adverse effects of abnormal genetic factors. It can effectively reduce the prevalence of children's malocclusion and enhance their physical and mental health. This is an urgent need from the economic perspective of our society, so it has great practical and social significance. Experts from the project group "standard diagnose and treatment protocols for early orthodontic intervention of malocclusions of children" which initiated by China National Health Institute of Hospital Administration wrote the "China Experts' Consensus on Preventive and Interceptive Orthodontic Treatments of Malocclusions of Children", which aims to guide and popularize the clinical practice, improve the clinical theory and practice level, and accelerate the disciplinary development of early treatment of children's malocclusion in China. The consensus elaborates the harmfulness of malocclusion and the necessity of early treatment, and brings up the principles and fundamental contents. Based on the law of dental and maxillofacial development, this paper puts forward the guiding suggestions of preventive and interceptive treatments in different stages of dental development ranging from fetus to early permanent dentition. It is a systematic project to promote and standardize the early treatment of malocclusion. Through scientific and comprehensive stratified clinical practice and professional training, the clinical system of early treatment of malocclusion in China will eventually be perfected, so as to comprehensively care for children's dental and maxillofacial health, and improve their oral and physical health in China.
		                        		
		                        		
		                        		
		                        			Child
		                        			;
		                        		
		                        			China/epidemiology*
		                        			;
		                        		
		                        			Consensus
		                        			;
		                        		
		                        			Dental Care
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Malocclusion/prevention & control*
		                        			;
		                        		
		                        			Orthodontics, Interceptive
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail